Market Overview

Philip Morris' Weakness In Japan, South Korea Sparks Cowen Downgrade

Philip Morris' Weakness In Japan, South Korea Sparks Cowen Downgrade
Related PM
Better Late Than Never: How The Tobacco Industry Could Benefit From Pot
How Long Before The FDA Could Ban Menthol Cigarettes?
Just Retired? Combine These Strategies To Earn Solid Income With Less Risk (Seeking Alpha)

Philip Morris International Inc. (NYSE: PM) reported second-quarter results Thursday that prompted Cowen drop its bullish stance on the cigarette maker. 

The Analyst

Cowen's Vivien Azer downgraded Philip Morris from Outperform to Market Perform with a price target lowered from $99 to $85.

The Thesis

Philip Morris' earnings report was accompanied with a downward revision to its earnings guidance, which is clearly disappointing to investors, Azer said in the downgrade note. (See the analyst's track record here.) 

The company does deserve some credit for the transparency in its revision, the analyst said. Cowen adjusted multiple assumptions related to the IQOS smokeless tobacco device: 

  • Total 2018 IQOS  shipment volumes were lowered from 45.5 billion to 39.5 billion.
  • Sequential share losses in Japan in the third and fourth quarter are projected at 40 basis points versus 30-basis point losses in the second quarter.
  • Flat performance in South Korea in the third and fourth quarter versus a 70-basis point gain in the second quarter.

Even if Philip Morris sees upside in IQOS shipments in other markets across Europe and Russia, it's unlikely they would be large enough to offset poorer performance in key markets like Japan and South Korea, which combine for 70 percent of total volumes, Azer said. 

Philip Morris's upcoming analyst meeting in late September could prove to be a catalyst, but without a large reversal in Japan and South Korea, any upside in the near-term is "more muted," according to Cowen. 

Price Action

Philip Morris shares were trading up 3.57 percent to $83.79 at the time of publication Friday afternoon. 

Related Links: 

What To Make Of The FDA Vote That Rocked Philip Morris

Altria's Problems Baked Into Price, Now A Buy At RBC

Latest Ratings for PM

Oct 2018CitigroupMaintainsBuyBuy
Oct 2018BernsteinInitiates Coverage OnOutperform
Sep 2018CitigroupMaintainsBuyBuy

View More Analyst Ratings for PM
View the Latest Analyst Ratings

Posted-In: cigarettes CowenAnalyst Color Earnings News Downgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (PM)

View Comments and Join the Discussion!

A Fantastic FERC Gift For MLP ETFs

Baird Downgrades Express Scripts On Industry Instability